Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b study of BGB-43395 alone or with fulvestrant or letrozole in metastatic HR-positive/HER2-negative breast cancer and other advanced solid tumors
jRCT2031240404Phase 1Active, not recruiting
- Sponsor
- BeiGene
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of bgb-43395 in breast cancer and Nonhematologic neoplasms (3 arms), sponsored by BeiGene. Primary endpoints: Number of participants with adverse events and serious adverse events, Maximum tolerated dose or maximum administered dose of BGB-43395 and 2 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
bgb-43395
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240404.